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Background: In the first phase of life, in which the immune system is primed and the bacterial colonization of
epithelial surfaces takes place, foals are highly susceptible to bacterial infections. Next to strategies to optimize
maternally acquired immunity in individual foals, current research explores other options to modulate immune
responses in foals. During the past decades, oligosaccharide supplements were developed to mimic beneficial
properties of the oligosaccharides, which are present in colostrum and milk. In human infants and laboratory animal
species, dietary supplementation with galacto-oligosaccharides (GOS) has been shown to result in prebiotic and
immunomodulating effects, with long-term beneficial consequences for both defensive and allergic immune
responses. As yet, no studies are published concerning the in vivo effects of GOS in horses. The current study was
designed as a pilot study to investigate the effects of an orally applied, commercially available GOS product in a
group of pony foals. The treatment and the control group consisted of six and four foals, respectively. Foals were
treated during the first four weeks of life and subsequently followed up for another ten weeks.
Results: In peripheral blood mononuclear cells (PBMCs) derived from GOS-treated foals at day 28, a standardized
lipopolysaccharide challenge resulted in significantly lower relative mRNA expression levels of the pro-inflammatory
cytokines interferon-γ and interleukin-6 compared with PBMCs of control foals. In the 98-day period of investigation,
no significant effects of the GOS supplement were observed on clinical and blood parameters for immunity and
general health in these foals.
Conclusions: Based on these first results, we can conclude that this dose regimen of GOS was well accepted by
the foals and did not result in any detectable undesirable side effects. More clinical trials are required to confirm
the attenuating effects of GOS treatment on equine pro-inflammatory immune responses and to implement this
into practice.
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With birth, the foal’s immune system is subjected to a
range of environmental challenges. Bacterial colonization
of epithelial surfaces is one of the major events in early
life determining immune responses in later phases of life
[1]. In addition to the basic concept of protection by ma-
ternal antibodies present in colostrum, recently more* Correspondence: J.C.Vendrig@uu.nl
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unless otherwise stated.interest has arisen for the influence of other colostral
constituents, such as oligosaccharides. In human infants
and experimental animals, dietary supplements containing
commercially produced galacto-oligosaccharides (GOS)
have been proven to elicit prebiotic effects [2-4] and to be
beneficial for health in several ways [5], for instance by en-
hancing defensive immune responses [6-8] and lowering
the incidence of infections [9,10]. Still, the evidence sup-
porting the use of such oligosaccharide supplements is
not conclusive, as other studies have reported only tem-
porary or non-significant effects of similar supplements
on infection and immunity [11-13].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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saccharides in horses has been conducted so far. Pre-
biotic properties of short-chain fructo-oligosaccharides
in horses have been confirmed [14,15], but to our know-
ledge no studies into in vivo effects of GOS or other
oligosaccharide supplements in horses or foals have been
published. Our previous in vitro studies with equine
peripheral blood mononuclear cells (PBMCs) revealed
immunomodulatory properties of both equine colostral
carbohydrates and several commercially available oligo-
saccharide products, including GOS [16,17].
The present study was designed as a pilot study to in-
vestigate the in vivo effects of a commercially available
GOS product in young foals. Next to assessing the safety
of the chosen dose regimen of GOS and its effects on
immunity and general health, we compared the respon-
ses to a standardized lipopolysaccharide (LPS) challenge
in ex vivo PBMCs after 4 weeks of treatment.Methods
Foals
Twelve warmblood pony foals (crossbreed New Forest*
Arabian) were included in the study, all born at a horse
dairy farm in The Netherlands, where the experiment
was carried out. All mares and foals were housed to-
gether as a group under identical and stable conditions.
Foals were born by natural delivery within a period of
ten weeks and were allocated to the treatment group
and the control group at random. In total, six foals were
supplemented with GOS and four foals were included in
the control group (two foals were excluded during the
course of the study: see results section). Foals were na-
turally nursed by the mares and were also free to eat
roughage (hay, grass, straw) as soon as they were ready
for it. All experimental procedures were approved by the
committee of ethical considerations in animal experiments
of Utrecht University (DEC Utrecht, Permit Number:
2012.III.05.053).Dietary supplementation
Foals in the treatment group were orally supplemented
with GOS for 28 days, starting at the day of birth. The
applied GOS product (Vivinal GOS syrup, Friesland-
Campina Domo, Zwolle, The Netherlands) consisted of
approximately 45% GOS, 16% lactose, 14% glucose, and
25% water. The product contained short chain GOS,
which are oligomers (degree of polymerization 2–6) con-
structed from lactose [18]. An amount of 15 g GOS
syrup was supplemented twice daily. Foals in the control
group were orally supplemented with 2.4 g lactose and
2.1 g glucose (twice daily for 28 days), resembling the
amounts of glucose and lactose that the GOS treated
foals received through the GOS syrup. Both the GOSsyrup and the control treatments were administered dir-
ectly into the mouth of the foals (with a syringe).
Sampling and output parameters
At day 0, 1, 7, 14, 21, 28, 42, 56, 70, 84, and 98, ap-
proximately 14 mL of blood was collected by jugular
venipuncture directly into sterile blood collection tubes;
one 10 mL serum tube and one 4 mL spray-coated
EDTA tube (BD Vacutainer Systems, Plymouth, United
Kingdom). At all time points, samples were sent to the
University Veterinary Diagnostic Laboratory in Utrecht
to determine red and white blood cell parameters (includ-
ing hematocrit, leukocyte count, and leukocyte differenti-
ation) and the total protein concentrations including a
protein electrophoresis (albumin and differentiation of
globulins). In addition, aliquots of the serum samples were
stored at −80°C to perform several ELISAs. Serum con-
centrations of the immunoglobulin subtypes IgG(a), IgG
(b), IgG(T), IgM and IgA were quantified, using commer-
cial ELISA kits according to the manufacturer’s instruc-
tions (Bethyl Laboratories Inc., Montgomery, AL, USA).
Mare colostrum was sampled within 12 hours postpar-
tum to investigate the concentrations of immunoglobu-
lin subtypes by means of the same ELISA kits (Bethyl
Laboratories Inc., Montgomery, AL, USA).
PBMC experiments
At day 28, the last day of GOS application, PBMCs were
isolated from each foal according to previously described
methods [16]. PBMCs were resuspended in RPMI 1640
Medium (Lonza, Basel, Switzerland) containing 2 mM
glutamine (Lonza, Basel, Switzerland), 100 IU/mL peni-
cillin (Lonza, Basel, Switzerland), 100 μg/mL streptomycin
(Lonza, Basel, Switzerland) and 10% horse serum. Horse
serum was prepared by collecting full blood, allowing it to
clot for 45 minutes, and then collecting the serum follow-
ing centrifugation. The serum for all experiments was pre-
pared at once by collection of blood from one pony (not
enrolled in the study) from the same herd.
PBMCs were seeded in 24 well plates at a density of
4*106 cells/mL medium/well. Subsequently, the plates
were incubated for 2 hours at 37°C and 5% CO2. The
plates were then centrifuged for 10 minutes at 400× g
before refreshing the medium without removing PBMCs.
The experiments were started by replacing the medium
with medium containing 0 or 1 μg/mL LPS (Escherichia
coli O111:B4, Sigma-Aldrich, St. Louis, MO, USA). After
4 hours of incubation, supernatants were collected for
ELISA and stored at −80°C; for qPCR, PBMCs were lysed
using RNA lysis buffer (Promega, Madison, WI, USA) and
stored at −80°C. All individual incubations were per-
formed in triplicate for each foal.
Protein levels of tumor necrosis factor-α (TNF-α),
interferon-γ (IFN-γ) and interleukin-10 (IL-10) were
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natants, using Duoset® ELISA Development System for
equine TNF-α, equine IFN-γ, and equine IL-10 (R&D
Systems, Minneapolis, MN, USA). Standard operating
procedures of the manufacturer were followed, applying
all required buffers and solutions in the form provided
by the manufacturer (R&D Systems, Minneapolis, MN,
USA). The lower limits of detection of the ELISAs were
15.6 pg/mL, 62.5 pg/mL, and 156.3 pg/mL for TNF-α,
IFN-γ, and IL-10, respectively.
RNA was isolated from PBMCs using SV Total RNA
isolation system according to the manufacturer’s instruc-
tions (Promega, Madison, WI, USA). Isolated fractions
were dissolved in 50 μL RNAse free water and stored
at −80°C. Quality and quantity of RNA was determined
spectrophotometrically (Nanodrop). cDNA was generated
using iScript™ cDNA Synthesis Kit (Biorad, Hercules, CA,
USA) according to the manufacturer’s protocol. For re-
verse transcriptase reaction, 1000 ng RNA was applied
per sample. Expression of mRNA was assessed by real-
time PCR using a Biorad iQ5 Multicolor Real-time
PCR detection system and iQ™ SYBR® Green Super-
mix (Biorad, Hercules, CA, USA). Specific primer pairs
were designed and tested for efficiency and accuracy,
after having checked their specificity using the NCBI-
BLASTN search program. Primer pairs were synthesized
commercially (Eurogentec Nederland B.V., Maastricht,
The Netherlands). For this study, mRNA expression of
IFN-γ, IL-4, IL-6, IL-10, IL-13, IL-17, transforming growth
factor-β1 (TGF-β1), TNF-α, β-actin, and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was determined
using the following primer pairs:
IFN-γ: F 5′-GATCTGAAGGTCCAGCGCAA-3′ R
5′-TCCGGCCTCGAAATGGATTC-3′;
IL-4: F 5′-GCCCGAAGAACACAGATGGA-3′ R
5′-CAGTACAGCAGGTCCCGTTT-3′;




IL-13: F 5′-AGCAGTCATTGCTCTCGCTT-3′ R
5′-TGGGTGATGTTGACCAGCTC-3′;
IL-17: F 5′-GCTGAGTCTGGTGGCTATCG-3′ R
5′-TTCTTGTCCCCAGTGTTCGG-3′;
TGF-β1: F 5′-TGTCCACCTGCAAGACCATC-3′ R
5′-CCGCAACTTGGACAGGATCT-3′;





GAPDH: F 5′-TGGCATGGCCTTCCGTGTCC-3′ R
5′-GCCCTCCGATGCCTGCTTCAC-3′.Statistical analysis
Data were analyzed in a Bayesian framework. This means
that we considered the data as fixed (which it is once ob-
served) and parameters as random variables because they
are unknown (in a frequentist framework, data are consid-
ered random and parameters are fixed). In other words,
our inferences are conditioned on the observed data, and
not on the distribution of test statistics across a range of
unobserved repeated samples. Related to this, the Bayesian
context facilitates a common-sense interpretation of un-
certainty in parameter estimates [19]. For example, a pos-
terior 95% credible interval of 1–10 means that the true
value of the parameter lies between one and ten with 95%
probability (conditional on the chosen model). Model se-
lection can be done based on the deviance-based informa-
tion criterion (and several other criteria), which can even
be used to compare hierarchical models. Also, a Bayesian
framework provides more robust parameter estimates, as
such estimates are exact (we need not rely on asymptotic
theory as we would in a frequentist framework) and we do
not have to be concerned about multiple testing. These
last two points are especially relevant to the current study
(small sample size, many outcome parameters).
Data on blood parameters (day 28 separately, and the
entire period from day 0–98) as well as PBMC data (day
28 only) were analyzed by means of Bayesian linear regres-
sion. Similar to previous analyses [17], PBMC responses
were allowed to vary between horses in general (random
intercept), and with regard to incubation with LPS (ran-
dom slope). To stabilize the variance, all blood and PBMC
data were log-transformed, except for hematocrit data,
which were analyzed on the unit scale. For the analysis of
the blood data over the entire period, time was entered
into the model as a continuous variable. To account for
the sometimes non-linear association between time and
blood data, time was transformed by means of fractional
polynomials, such that the statistical model best fitted the
data. To minimize bias in blood data due to variable up-
take of colostral globulins, the first weeks of life were not
included in the analysis for β-2 and γ globulins (up to day
42), IgA and IgM (up to day 28), IgG(a) (up to day 42),
and IgG(b) and IgG(T) (up to day 56). The selection of
these periods was based on visual inspection of the data,
and was made such that at worst, estimates of the dif-
ference between the control and GOS group would be
conservative.
For each data type, the best fitting fractional polyno-
mials were determined in R (version 2.15.3; [20]), using
the package mfp (version 1.4.9; [21]), not yet accounting
for variation between horses. Final models, including
random intercepts and fractional polynomials, were ana-
lyzed in JAGS, a program for analysis of Bayesian models
using Markov Chain Monte Carlo simulation (version
3.3.0; [22]). Simulations in JAGS were performed using
Table 1 Blood parameters: comparison between
GOS-treated and control foals throughout the 98 days of
the experiment
Difference between treatment
and control group including





Leukocytes 0.88 0.66 1.15
Lymphocytes 0.89 0.66 1.19
Mature granulocytes 0.89 0.62 1.28
Total protein2 1.03 0.94 1.13
Albumin (absolute values) 1.05 0.96 1.15
α-1 globulins (absolute values) 1.09 0.87 1.36
α-2 globulins (absolute values) 0.94 0.84 1.04
β-1 globulins (absolute values) 1.16 0.72 1.97
β-2 globulins (absolute values) 1.05 0.74 1.54
γ globulins (absolute values) 1.10 0.83 1.44
Albumin (% of total protein) 1.01 0.94 1.09
α-1 globulins (% of total protein) 1.05 0.83 1.36
α-2 globulins (% of total protein) 0.91 0.81 1.02
β-1 globulins (% of total protein) 1.09 0.74 1.61
β-2 globulins (% of total protein) 1.01 0.71 1.44
γ globulins (% of total protein) 1.07 0.87 1.30
IgA 1.02 0.66 1.55
IgM 1.20 0.72 1.99
IgG(a) 1.13 0.91 1.42
IgG(b) 1.77 0.66 4.99
IgG(T) 1.34 0.74 2.38
1Relative differences are stated (significant if ≠ 1). For the hematocrit, the
absolute difference was 0.00 (interval ranging from −0.04 to 0.05). 2The
protein spectrum (albumin and different globulins) are compared both as
absolute values (g/L) and as a percentage of the total protein concentration.
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0.03-08; [24]). Posterior distributions were estimated
based on uninformative prior distributions (normal dis-
tributions with mean 0 and standard deviation 100 for
parameter means; inverse gamma distributions with mean
1 and variance 10,000 for variance of measurement error;
uniform distributions with range 0 to 100 for standard de-
viation of random intercepts). Differences between control
and GOS groups were stated significant, based on 95%
Bayesian credible intervals, which were defined as the
2.5% and 97.5% percentiles of the posterior distributions.
Posterior distributions were simulated by means of four
Markov chains, each consisting of 10,000 Monte Carlo
samples. The first 5,000 samples were discarded for burn-
in, allowing the model to converge. Model convergence
was assessed by means of Gelman and Rubin’s conver-
gence diagnostic, the potential scale reduction factor [25].
qPCR data validation
Variation of mRNA expression was excluded as a con-
founding factor, as no significant differences in either
β-actin or GAPDH expression were detected between
PBMCs from GOS-treated foals and foals from the
control group, or between the blank incubations and
the incubations with LPS.
In addition, we analyzed the data with a correction for
GAPDH, according to the method described by Livak
and Schmittgen [26]. In our case, normalization of data
(based on housekeeping genes) did not change point es-
timates for differences between incubation types. Fur-
thermore, normalization did not reduce the variation in
the data (as should be expected in case of confounding
due to variation in total mRNA levels), but rather in-
creased it. This indicated that the error due to variation
in mRNA expression, if any, was negligible compared
to basic measurement error in the data. Based on this
knowledge and the fact that housekeeping genes for
equine PBMCs have not yet been validated, we deci-
ded to present the data in this manuscript without any
corrections.
Results
Course of the study
During the 98-day period of investigation, no effects of
the treatment on the apparent clinical health parameters
were observed, either in the GOS-treated foals or in the
control group. The treatments were well accepted by the
foals and no undesirable side effects (including diarrhea)
were encountered.
Two foals in the control group were excluded from
the study; one foal was stillborn, and another foal was
not treated on the first two days of life due to colic.
Therefore, the results comprise the data of six GOS-
treated foals and four foals from the control group.Blood parameters
Table 1 represents the comparison of the blood parame-
ters between GOS-treated and control foals during the
entire period of investigation. None of the blood param-
eters differed significantly between the two groups of
foals. In Figure 1, a quantification of blood parameters is
given for all foals at each time point for the entire period
of investigation. Table 2 illustrates the comparison of the
blood parameters between the two groups of foals at day
28 (at the moment of PBMC isolation). At day 28, the
blood concentration of IgG(a) was found to be signifi-
cantly higher in the group of GOS-treated foals com-
pared to control group. Apart from this, no significant
differences were observed between the two groups at
day 28.
An additional file is provided to illustrate the data in
more detail for the individual foals in both groups (see
[Additional file 1]).
Figure 1 Blood parameters. Mean values and standard deviations for the investigated blood parameters at each time point for all foals
included in the study.
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The measured concentrations of immunoglobulin sub-
types in the colostral samples of the individual mares are
added to the immunoglobulin data of the correspond-
ing foals in the provided additional file (see [Additional
file 1]). No significant differences were observed with
regard to concentrations of the measured immunoglo-
bulin subtypes in the mares’ colostrum between the two
groups. The colostral immunoglobulin levels for all mares
exceeded the minimal quality standards for equine colos-
trum (for instance 3000 mg/dL for IgG [27]). Moreover,
the colostrum of the dams of foals with relatively lowserum globulin concentrations during the first weeks did
not contain lower amounts of immunoglobulins relative
to the colostrum of dams belonging to foals with high
serum globulin concentrations.
The passive transfer of immunity at day 1 was within
the expected range, as all foals reached serum IgG con-
centrations well above 800 mg/dL, except for one foal in
the control group (i.e., 294 mg/dL 24 hours postpartum).
In the analysis of endogenously produced immunoglobu-
lins, no significant differences were found in the entire
group of foals and the serum of the aforementioned foal
reached comparable immunoglobulin concentrations as
Table 2 Blood parameters: comparison between
GOS-treated and control foals at day 28 (at the moment
of PBMC isolation)
Difference between treatment
and control group including





Leukocytes 0.85 0.47 1.57
Lymphocytes 0.83 0.60 1.15
Mature granulocytes 0.83 0.34 2.02
Total protein2 1.03 0.92 1.16
Albumin (absolute values) 0.99 0.87 1.14
α-1 globulins (absolute values) 1.01 0.77 1.33
α-2 globulins (absolute values) 1.06 0.82 1.36
β-1 globulins (absolute values) 1.18 0.68 2.02
β-2 globulins (absolute values) 1.14 0.63 2.01
γ globulins (absolute values) 1.11 0.61 2.02
Albumin (% of total protein) 0.96 0.87 1.08
α-1 globulins (% of total protein) 0.98 0.71 1.37
α-2 globulins (% of total protein) 1.03 0.81 1.29
β-1 globulins (% of total protein) 1.15 0.70 1.88
β-2 globulins (% of total protein) 1.10 0.62 1.95
γ globulins (% of total protein) 1.07 0.64 1.81
IgA 1.41 0.92 2.18
IgM 1.15 0.62 2.08
IgG(a) * 1.43 1.10 1.83
IgG(b) 2.14 0.58 7.99
IgG(T) 1.70 0.56 5.00
1Relative differences are stated (significant if ≠ 1, marked with asterisk). For the
hematocrit, the absolute difference was −0.01 (interval ranging from −0.07 to
0.06). 2The protein spectrum (albumin and different globulins) are compared
both as absolute values (g/L) and as a percentage of the total
protein concentration.
Figure 2 TNF-α production. Mean supernatant concentrations of
TNF-α (in pg/mL) including 95% Bayesian credible intervals for
unchallenged (blank) and LPS-challenged PBMCs derived from foals
treated with either GOS or glucose/lactose (control).
Vendrig et al. BMC Veterinary Research 2014, 10:278 Page 6 of 10
http://www.biomedcentral.com/1746-6148/10/278well (in the period >42 days of age, as can be observed
in the graphs of [Additional file 1]).
PBMC experiments
Figure 2 illustrates supernatant concentrations of TNF-α
for unchallenged and LPS-challenged PBMCs. No sig-
nificant difference in TNF-α production was observed
between the two groups. The data for supernatant con-
centrations of IL-10 and IFN-γ were mostly below the
detection limit of the applied assay. Hence, analysis of
these data was not possible.
Relative cytokine expression levels after LPS stimulation
in PBMCs are presented in Figure 3. In both groups,
ex vivo LPS stimulation resulted in a significant up-
regulation of mRNA expression for all investigated cyto-
kines, except IL-4 and TGF-β1. IL-4 expression was not
significantly influenced by the LPS challenge in neither ofthe groups, and the expression of TGF-β1 was signifi-
cantly down-regulated in both groups. For IFN-γ and
IL-6, the relative mRNA expression levels after LPS
challenge were significantly lower in PBMCs derived
from GOS-treated foals compared with the control
group (80% and 40% reduction for IFN-γ and IL-6, re-
spectively). No other significant differences were de-
tected between the two groups.
Discussion
In this pilot study, we found that GOS was well accepted
and tolerated by newborn foals, causing no observable
negative side effects. Furthermore, we did not find any
significant differences between GOS-treated and control
foals with regard to the investigated blood parameters.
The serum globulin contents varied highly during the
first weeks of life, most likely due to differences in the
uptake of maternal globulins by individual foals. The
measured globulin concentrations of the colostrum sam-
ples indicate that this variation was not caused by in-
sufficient quality of the mares’ colostrum. Despite the
variation in maternally acquired immunoglobulin levels,
all foals eventually reached comparable and sufficient
levels of immunoglobulins during the experimental
period, through endogenous production (in the period >42
days of age). This active immunity of the foal itself becomes
pivotal to prevent pathogens from causing disease, when
maternal immunity fades [28].
At the moment of PBMC isolation, no significant dif-
ferences were observed among the blood parameters of
Figure 3 Cytokine mRNA expression levels. Mean relative cytokine mRNA expression levels including 95% Bayesian credible intervals in
LPS-challenged PBMCs, relative to blank controls. Significant differences between PBMCs derived from foals treated with GOS and glucose/lactose
(control) are indicated with an asterisk (*).
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IgG(a), which was significantly higher in the group of
GOS-treated foals compared to the control group (see
Table 2). This difference can be attributed to the parti-
cularly low serum IgG(a) concentration of the one foal
with failure of passive transfer. One may be concerned
about a possible influence of the serum IgG(a) concen-
tration on the mRNA expression of cytokines in the
foals’ PBMCs following LPS stimulation. If this were the
case, one would expect particularly high mRNA expres-
sion rates for IFN-γ and IL-6 in the PBMCs of foals with
relatively low serum IgG(a) concentrations. However,
such a pattern was not present in our data; in contrast,
the data showed relatively low mRNA expression levels
of IFN-γ and IL-6 for the PBMCs of foals with relatively
low IgG(a) concentrations. Therefore, we conclude that
the differences in the PBMC experiments were probably
not caused by differences in serum IgG(a) concentra-
tions at day 28.
Our results show that the LPS-induced mRNA expres-
sion levels of IFN-γ and IL-6, which are both related to
type 1 T helper cell (Th1) responses, were significantly
lower in PBMCs derived from GOS-treated foals com-
pared with the control group. However, the LPS-induced
production of TNF-α in PBMCs did not differ betweenthe two groups; similarly, there was no significant dif-
ference in mRNA expression of TNF-α. Recently, anti-
inflammatory effects of oligosaccharide supplements
containing GOS have been described in preterm human
infants as well, though these effects were found to be
transient [12]. Therefore, the PBMC data from our pilot
study in foals call for future studies with PBMC expe-
riments at multiple time points during the treatment
period.
Several studies have reported measurable immunomo-
dulatory effects of oligosaccharides through direct inter-
action with Toll-like receptors (TLRs) [29-31]. Moreover,
transfer of oligosaccharides across the epithelial barrier
was proven by Eiwegger et al.[32], suggesting that direct
contact between orally supplied oligosaccharides and the
cells of the immune system is possible. Taking these find-
ings into account, we hypothesize that oral supplementa-
tion of GOS in the present study led to long-term in vivo
interaction of PBMCs with TLRs, eventually resulting
in a measurable endotoxin tolerance and less respon-
sive PBMCs. This hypothesis is in line with our data
from a previous study, in which we demonstrated direct
(short-term) immunomodulatory effects of GOS on equine
PBMCs ex vivo; co-incubation of equine PBMCs with
GOS enhanced the LPS-induced cytokine responses [16].
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strated in several cell types [33,34]. To investigate this
further, future in vitro experiments with repeated or long-
term exposure to oligosaccharides are desirable. However,
the limited viability of primary equine cells and the lack of
a functional equine immortal cell line make it difficult to
perform reliable experiments over a longer time frame.
Young foals have previously been shown to display
lower expression levels of Th1 related cytokines, includ-
ing IFN-γ and IL-6, compared with older individuals
[35-37]. Immature lymphocyte responses in neonates,
with a bias towards Th2 responses, are thought to play a
role in the increased susceptibility to infections in early
life. Therefore, immunomodulation in young individuals
is generally focused on the enhancement of defensive
cytokine responses instead of reducing them [38]. On
the other hand, a modulated immune response to bac-
teria that colonize epithelial surfaces during the first
period of life, including the intestines, is a prerequisite
to establish bacterial colonization and concurrently main-
tain homeostasis [39]. Exaggerated immune responses to
bacteria in the phase of colonization could influence the
composition of the microbiota and even may cause tissue
damage and decreased epithelial barrier function, possibly
leading to bacterial infections and sepsis. If indeed GOS
treatment in foals results in a lower responsiveness of gut-
associated lymphocytes and dendritic cells to LPS (or
other challenges), this could be an interesting finding with
regard to the eventual introduction of oligosaccharide
supplements in practice. Depending on the clinical con-
text, next to disease prevention through enhancing defen-
sive immune responses, the suppression of exaggerated
cytokine responses to bacterial compounds could prevent
pathology in early life, particularly in the gastrointestinal
tract. On the other hand, very pronounced suppression of
immune responses by GOS is not desirable as it could
increase the susceptibility to infections. This question
should be addressed in forthcoming in vivo experiments
that include a pathogen challenge of treated foals. More
research is required to further investigate the long-term
effects of GOS, other oligosaccharides, and oligosacchar-
ide mixtures, and to eventually optimize the use of oligo-
saccharide supplements in different clinical settings.
In addition, beneficial effects of oligosaccharide sup-
plements on allergic immune responses have been re-
ported in various mammalian species [40-45]. Recently,
a Cochrane review was published on this subject, in
which these significant beneficial effects are stated as
well, together with the limitations of these studies and
the need for more conclusive evidence [46]. The re-
ported beneficial effects of oligosaccharide supplements
in other species suggest another possible indication for
the use of oligosaccharides in horses, with the aim to re-
duce the long-term incidence and severity of relevantimmune-mediated inflammatory diseases, such as recur-
rent airway obstruction, inflammatory airway disease,
and insect hypersensitivity (summer eczema). Further in-
vestigations into this topic are warranted.
Conclusions
In conclusion, the results from this pilot study indicate
that the chosen dose regimen of GOS was well accepted
by the foals, and that no undesirable side effects were
encountered. At the same time, no differences in the in-
vestigated hematological parameters, including serum
immunoglobulins, could be detected between GOS-treated
foals and the control group. GOS treatment appeared to
reduce the pro-inflammatory responses in PBMCs after an
ex vivo LPS challenge. With this knowledge, additional ex-
periments with the GOS preparation can be performed in
larger groups of foals, including the application of higher
dosages and longer periods of treatment. Moreover, a lon-
ger follow up of GOS-treated foals may reveal long-term
beneficial effects on the incidence and severity of immune-
mediated inflammatory diseases, in line with published
studies in other mammalian species.
Additional file
Additional file 1: Investigated blood and colostrum parameters in
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white blood cell counts (leukocytes, lymphocytes, mature granulocytes)
and protein electrophoresis (total protein, albumin, α-, β-, γ-globulins) for
blood samples, and immunoglobulin subtypes (IgA, IgM, IgG(a), IgG(b),
IgG(T)) for blood and colostrum samples.
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